1. Zowawi HM, Harris PNA, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, Williamson DA, Paterson DL. The emerging threat of multidrug-resistant gram-negative bacteria in urology. Nat Rev Urol. 2015;12:570–84.
2. Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, Bjerklund JT. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014;32:791–801.
3. Bonkat G, Pickard R, Bartoletti R, Bruyère F, Geerlings SE, Wagenlehner F, Wullt B, Cai T, Köves B, Pilatz A, Pradere B, Veeratterapillay R. EAU guidelines on urological infections. Arnhem: European Association of Urology; 2017. http://uroweb.org/guideline/urological-infections/. Accessed 31 Jan 2018.
4. Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int. 2018;100(3):271–8. https://doi.org/10.1159/000487645.
5. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–56.